Story
Genmab Stock Surges on Q2 Earnings Beat and Upgraded Outlook

Shares of Genmab (GMAB) surged 9.2% to DKK 2,050 in trading after the Danish biotechnology company reported a strong second-quarter earnings beat, raised its full-year financial guidance, and announced positive clinical and regulatory updates.
Stronger-Than-Expected Financials
Genmab posted second-quarter earnings per share of $0.49, significantly exceeding the consensus analyst estimate of $0.37. Quarterly revenue also came in ahead of expectations at $1.16 billion, compared to the $1.11 billion anticipated by analysts.
Following the strong performance, the company lifted its full-year revenue guidance to a new range of $4.325 billion to $4.525 billion. According to the company, the improved outlook is driven by expectations for higher royalty revenues from its cancer drug DARZALEX and stronger net sales of EPKINLY.
Clinical and Commercial Momentum
The company's growth was underpinned by robust product performance and key pipeline developments. Genmab highlighted several positive updates:
Ad- Royalty revenue reached $1.708 billion, a year-over-year increase of 24%.
- Global net sales for EPKINLY/TEPKINLY surged 48% to $312 million.
- The Phase III EPCORE DLBCL-2 study delivered statistically significant and clinically meaningful results for progression-free survival.
- EPKINLY received European approval for use in combination with other therapies for second-line follicular lymphoma.
In a statement, CEO Jan van de Winkel noted that its drug epcoritamab "continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies."
Market Context
The sharp upward move in Genmab's stock was amplified by a positive backdrop for the broader European healthcare sector, which rose 1.3% during the session. The combination of a substantial earnings beat, an increased forecast, and favorable drug development news provided investors with multiple catalysts to drive the stock higher, pushing it toward the upper end of its 52-week trading range of DKK 1,337 to DKK 2,257.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.